Last updated: February 15, 2026
What is the current market status of drug NDC 70165-0100?
The drug identified by NDC 70165-0100 is Emgality (galcanezumab-gnlm), marketed by Eli Lilly. It is a monoclonal antibody used to treat migraines and cluster headaches. Launched in 2018, Emgality generated approximately $300 million in U.S. sales during 2022, reflecting steady growth driven by expanding indications and patient acceptance.
The drug's primary competition includes Aimovig (erenumab) by Amgen and Novartis, and Ajovy (fremanezumab) by Teva. Emgality holds about 38% of the migraine CGRP monoclonal antibody market share in the U.S., with total migraine prevention biologic sales estimated at around $800 million annually.
How does the drug's market share and revenue compare?
| Metric |
Emgality (70265-0100) |
Aimovig |
Ajovy |
| Market share (2022) |
38% |
35% |
27% |
| U.S. Revenue (2022) |
$300 million |
$280 million |
$220 million |
| Growth rate (2021–2022) |
12% |
9% |
11% |
The market is characterized by incremental growth, driven by expanding approval for episodic and chronic migraine populations, as well as off-label uses in cluster headaches.
What are the key regulatory and pipeline developments?
- FDA approval for episodic and chronic migraine prevention.
- Pending or recent approvals in the European Union and Japan.
- Development of biosimilar versions has not yet entered the market; no approved biosimilars exist as of 2023.
- Eli Lilly is investigating extended dosing intervals and new formulations to enhance patient compliance.
What pricing trends are observed?
Current pricing
- The average wholesale price (AWP) per dose is approximately $725.
- Monthly treatment costs for a patient range between $2,000 and $3,000, depending on dosing schedules.
- Insurance reimbursement is common but often includes high copays, limiting accessibility for some populations.
Price projections (2023-2028)
| Year |
Estimated Price per Dose |
Estimated Monthly Cost |
Rationale |
| 2023 |
$725 |
$2,000 |
Stable due to established market and high-cost biologic nature. |
| 2024 |
$750 |
$2,200 |
Slight inflation, potential for new formulations. |
| 2025 |
$770 |
$2,300 |
Potential price increases related to new dosing strategies. |
| 2026 |
$790 |
$2,400 |
Competitive pressure may limit significant hikes. |
| 2027 |
$800 |
$2,500 |
Market stabilization, no biosimilar entry anticipated by 2028. |
Factors influencing price projections:
- Market competition: Biosimilar entrants are unlikely within the forecast window, maintaining premium pricing.
- Regulatory approvals: New indications could expand patient base, supporting sustained pricing.
- Manufacturing costs: Slight increases due to raw material prices could influence pricing.
- Reimbursement policies: Payer negotiations could pressure prices downward.
What are the primary drivers impacting market growth?
- Patient adoption rates: Improved convenience and broadened indications are expected to increase patient numbers.
- Ongoing clinical trials: Studies on additional indications, such as menstrual migraine, could expand market scope.
- Pricing pressures: Payers aim to reduce costs via formulary management, potentially influencing prescribing behaviors.
What are the potential risks to market expansion?
- Emergence of biosimilars or generics could erode market share.
- Regulatory delays for new indications or formulations may hinder growth.
- Market saturation in key demographics might slow revenue increases after 2025.
Summary of key insights
- Emgality holds a significant but competitive segment in the migraine biologics market.
- Revenue growth is steady, with total U.S. sales around $300 million in 2022.
- Price points are expected to increase modestly, maintaining premium status absent biosimilar competition.
- Market expansion depends heavily on regulatory approvals, clinical trial outcomes, and payer acceptance.
Key Takeaways
- Emgality's market share remains stable amid competition.
- Pricing is projected to increase slightly but remain high due to brand loyalty and lack of biosimilars.
- Revenue growth is contingent upon new indications and global expansion.
- Biosimilar entry risks could alter future market dynamics beyond 2028.
- Cost management and payer negotiations will influence future pricing strategies.
FAQs
1. When might biosimilars for galcanezumab enter the market?
Biosimilar development is currently at preclinical or early clinical stages, with approval timelines typically extending 6–10 years from initiation. No biosimilars have been approved as of 2023, making biosimilar entry unlikely before 2030.
2. How are new indications affecting Emgality's market potential?
Approval for additional indications such as menstrual migraines and cluster headaches expands the patient base, potentially increasing revenues by 10–20% over the next five years.
3. What factors could limit price increases for Emgality?
Increased payor pushback, biosimilar competition, or new competing therapies could constrain pricing flexibility, emphasizing value-based pricing strategies.
4. What is the potential impact of market saturation?
If most eligible patients are treated within five years, growth could plateau, leading to a stabilized revenue outlook after 2025.
5. How does Emgality compare with competing therapies in terms of reimbursement?
Reimbursement rates are comparable among CGRP inhibitors, with slight variations based on insurance formularies and negotiated discounts. Emgality maintains a slightly higher list price but faces competitive pressure to justify cost differences.
References
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- Eli Lilly. (2023). Emgality product label and pipeline updates.
- FDA. (2018). Emgality (galcanezumab-gnlm) approval announcement.
- EvaluatePharma. (2022). Biologic market outlook.
- MarketWatch. (2023). Biologic drug pricing trends.
